CoChat
Sign Up
Cited by 162Liver Disease Diagnosis and TreatmentLipid metabolism and biosynthesisCancer, Lipids, and Metabolism

The DOI matches its Crossref record; 68 of the 68 references it cites were found in a registry or an index.

Liver-Specific Expression of Transcriptionally Active SREBP-1c Is Associated with Fatty Liver and Increased Visceral Fat Mass

Open access
Knebel, Birgit, Haas, Jutta, Hartwig, Sonja, Jacob, Sylvia, Köllmer, Cornelia, Nitzgen, Ulrike, Muller–Wieland, Dirk, Kotzka, Jorg·2012·PLoS ONE
DOI 10.1371/journal.pone.0031812PMC PMC3283692
Open this paper in CoChat — free accountOpen PDF

Abstract

The pathogenesis of fatty liver is not understood in detail, but lipid overflow as well as de novo lipogenesis (DNL) seem to be the key points of hepatocyte accumulation of lipids. One key transcription factor in DNL is sterol regulatory element-binding protein (SREBP)-1c. We generated mice with liver-specific over-expression of mature human SREBP-1c under control of the albumin promoter and a liver-specific enhancer (alb-SREBP-1c) to analyze systemic perturbations caused by this distinct alteration. SREBP-1c targets specific genes and causes key enzymes in DNL and lipid metabolism to be up-regulated. The alb-SREBP-1c mice developed hepatic lipid accumulation featuring a fatty liver by the age of 24 weeks under normocaloric nutrition. On a molecular level, clinical parameters and lipid-profiles varied according to the fatty liver phenotype. The desaturation index was increased compared to wild type mice. In liver, fatty acids (FA) were increased by 50% (p<0.01) and lipid composition was shifted to mono unsaturated FA, whereas lipid profile in adipose tissue or serum was not altered. Serum analyses revealed a ∼2-fold (p<0.01) increase in triglycerides and free fatty acids, and a ∼3-fold (p<0.01) increase in insulin levels, indicating insulin resistance; however, no significant cytokine profile alterations have been determined. Interestingly and unexpectedly, mice also developed adipositas with considerably increased visceral adipose tissue, although calorie intake was not different compared to control mice. In conclusion, the alb-SREBP-1c mouse model allowed the elucidation of the systemic impact of SREBP-1c as a central regulator of lipid metabolism in vivo and also demonstrated that the liver is a more active player in metabolic diseases such as visceral obesity and insulin resistance.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0031812

Cites

68 of 68 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Tissue-specific over-expression of alb-SREBP-1c in vivo. (A) Scheme of the DNA constructs used to generate transgenic mice. The transcriptionally active N-terminal domain of the human SREBP-1c gene (aa 1–436 including a 5′-HA-tag (YPYDVPDYA) was inserted into a vector construct containing the mouse albumin promoter, a liver-specific enhancer element and a polyadenylation site. The SREBP-1c expression cassette was released by BssHI restriction for microinjection into male pronuclei of zygotes derived from C57Bl6 mice. (A) Verification of transgene insertion into genomic DNA was performed by PCR. M: size marker, genomic DNA of lane 1: C57Bl6, 2: alb-SREBP-1c, and lane 3: no template control. (B) Validation of transgene expression of alb-SREBP-1c animal model on mRNA level by RT-PCR. RNA extracted from snap-frozen liver biopsies from male alb-SREBP-1c and C57Bl6 mice was analyzed by RT-PCR with transgene human SREBP-1c (HA-SREBP-1c) , mouse SREBP-1a (m-SREBP-1a), mouse SREBP-1c (m-SREBP-1c) and mouse SREBP-2 (m-SREBP-2) specific primers and probe. The relative RNA amount shown in arbitrary units was calculated and plotted ± S.D. Graphs represent data from four male mice per genotype, each analyzed in triplicate (p<0.01). (C) Verification of transgene expression on protein level in liver. Protein extracts of snap-frozen liver biopsies from lane 1: alb-SREBP-1c, 2: C57Bl6 mice were separated by SDS-PAGE and blotted on nitrocellulose membrane. The membrane was probed with HA-specific antibody to determine the HA-tag of the transgene construct. A representative experiment is shown. For normalizing, blots were probed with α-tubulin antibody. (D) Graphs show densitometry evaluation of n = 5 independent experiments. (E) Tissue-specific expression of alb-SREBP-1c. Protein extracts of lane 1: liver, 2: pancreas, 3: skeletal muscle, 4: adipose tissue, 5: heart, 6: kidney and 7: small intestine were separated by SDS-PAGE, blotted and probed with HA-specific antibody. A representative experiment is shown. The arrow indicates HA-tagged SREBP-1c. For normalizing, blots were probed with α-tubulin antibody. (F) Graphs show densitometry evaluation of n = 5 independent experiments.
Figure 1 Tissue-specific over-expression of alb-SREBP-1c in vivo. (A) Scheme of the DNA constructs used to generate transgenic mice. The transcriptionally active N-terminal domain of the human SREBP-1c gene (aa 1–436 including a 5′-HA-tag (YPYDVPDYA) was inserted into a vector construct containing the mouse albumin promoter, a liver-specific enhancer element and a polyadenylation site. The SREBP-1c expression cassette was released by BssHI restriction for microinjection into male pronuclei of zygotes derived from C57Bl6 mice. (A) Verification of transgene insertion into genomic DNA was performed by PCR. M: size marker, genomic DNA of lane 1: C57Bl6, 2: alb-SREBP-1c, and lane 3: no template control. (B) Validation of transgene expression of alb-SREBP-1c animal model on mRNA level by RT-PCR. RNA extracted from snap-frozen liver biopsies from male alb-SREBP-1c and C57Bl6 mice was analyzed by RT-PCR with transgene human SREBP-1c (HA-SREBP-1c) , mouse SREBP-1a (m-SREBP-1a), mouse SREBP-1c (m-SREBP-1c) and mouse SREBP-2 (m-SREBP-2) specific primers and probe. The relative RNA amount shown in arbitrary units was calculated and plotted ± S.D. Graphs represent data from four male mice per genotype, each analyzed in triplicate (p<0.01). (C) Verification of transgene expression on protein level in liver. Protein extracts of snap-frozen liver biopsies from lane 1: alb-SREBP-1c, 2: C57Bl6 mice were separated by SDS-PAGE and blotted on nitrocellulose membrane. The membrane was probed with HA-specific antibody to determine the HA-tag of the transgene construct. A representative experiment is shown. For normalizing, blots were probed with α-tubulin antibody. (D) Graphs show densitometry evaluation of n = 5 independent experiments. (E) Tissue-specific expression of alb-SREBP-1c. Protein extracts of lane 1: liver, 2: pancreas, 3: skeletal muscle, 4: adipose tissue, 5: heart, 6: kidney and 7: small intestine were separated by SDS-PAGE, blotted and probed with HA-specific antibody. A representative experiment is shown. The arrow indicates HA-tagged SREBP-1c. For normalizing, blots were probed with α-tubulin antibody. (F) Graphs show densitometry evaluation of n = 5 independent experiments.CC BY · PubMed Central
Figure 2 Macroscopic and histological comparison of livers from C57Bl6 and alb-SREBP-1c mice. Panel (A) shows fatty liver macroscopically of a C57Bl6 (left) or alb-SREBP-1c (right) mouse. (B) Liver tissue of the Lobus caudatus, Lobus sinister- and Lobus dexter lateralis were used for (I) standard hematoxylin and eosin staining. (II) PAS staining was performed to determine glycogen content. (III) The tissues were also used for cryofixation, and Oil-red-O staining was used for lipid visualization. (IV) Fibers and the extra cellular matrix were visualized to determine tissue integrity. The overview magnification is 1∶10, and details are shown in 1∶100 magnification.
Figure 2 Macroscopic and histological comparison of livers from C57Bl6 and alb-SREBP-1c mice. Panel (A) shows fatty liver macroscopically of a C57Bl6 (left) or alb-SREBP-1c (right) mouse. (B) Liver tissue of the Lobus caudatus, Lobus sinister- and Lobus dexter lateralis were used for (I) standard hematoxylin and eosin staining. (II) PAS staining was performed to determine glycogen content. (III) The tissues were also used for cryofixation, and Oil-red-O staining was used for lipid visualization. (IV) Fibers and the extra cellular matrix were visualized to determine tissue integrity. The overview magnification is 1∶10, and details are shown in 1∶100 magnification.CC BY · PubMed Central
Figure 3 Phenotypical comparison of C57Bl6 and transgenic alb-SREBP-1c animals. Weight gain (A) and food intake (B) of male mice (n = 20 per genotype) were measured once a week starting at weaning and monitored for an observation period of 18 weeks. Food intake per body weight (C) and weight gain per food intake (D) were determined in each group of mice. Data are given as means including standard deviation (±S.D.). C57Bl6 vs. alb-SREBP-1c mice: **p<0.01.
Figure 3 Phenotypical comparison of C57Bl6 and transgenic alb-SREBP-1c animals. Weight gain (A) and food intake (B) of male mice (n = 20 per genotype) were measured once a week starting at weaning and monitored for an observation period of 18 weeks. Food intake per body weight (C) and weight gain per food intake (D) were determined in each group of mice. Data are given as means including standard deviation (±S.D.). C57Bl6 vs. alb-SREBP-1c mice: **p<0.01.CC BY · PubMed Central
Figure 4 Comparison of body composition of C57Bl6 and transgenic alb-SREBP-1c animals. Body weight (A), lean body mass (B), subcutaneous adipose tissue (C), visceral adipose tissue (E) and liver weight were determined at scarification at 24 weeks of age of male mice (n = 20 per genotype) and are given directly (A, B, C, E, G) and in relation to body weight (BW) (D, F, H). C57Bl6 vs. alb-SREBP-1c mice: *p<0.05; **p<0.01.
Figure 4 Comparison of body composition of C57Bl6 and transgenic alb-SREBP-1c animals. Body weight (A), lean body mass (B), subcutaneous adipose tissue (C), visceral adipose tissue (E) and liver weight were determined at scarification at 24 weeks of age of male mice (n = 20 per genotype) and are given directly (A, B, C, E, G) and in relation to body weight (BW) (D, F, H). C57Bl6 vs. alb-SREBP-1c mice: *p<0.05; **p<0.01.CC BY · PubMed Central
Figure 5 Macroscopic comparisons of C57Bl6 and transgenic alb-SREBP-1c animals. (A) First, sections of male mice at 24 weeks of age are shown. (B) Histology of visceral adipose tissue indicated hyperplasia but no signs of infiltration. All photographs were taken with the same magnification.
Figure 5 Macroscopic comparisons of C57Bl6 and transgenic alb-SREBP-1c animals. (A) First, sections of male mice at 24 weeks of age are shown. (B) Histology of visceral adipose tissue indicated hyperplasia but no signs of infiltration. All photographs were taken with the same magnification.CC BY · PubMed Central
Figure 6 Cytokine profile secreted from isolated adipocytes of C57Bl6 and transgenic alb-SREBP-1c animals. The cytokine content in supernatant of cultured primary adipocytes was analyzed using the Proteome Profiler™; R&D Systems, (Abingdon, UK). Spot intensities were normalized to background and positive controls set to 100% intensity. Presented numbers on membranes mark targets as follows: (1) CSF-3; (2) CSF-2; (3) CCL-1; (4) sICAM -; (5) IL-1ra; (6) IL-6; (7) CXCL-10; (8) CXCL-1; (9) CSF-1; (10) MCP-1; (11) MCP-5; (12) CXCL-9; (13) CCR-1a; (14) CXCL-2; (15) CCL-5; (16) TIMP-1. Abundance of: CXCL-13, C5a, CCL-11, IFN-γ, IL1-α, IL1-ß, IL-2, IL-3, IL-4, IL-5, IL-7, IL-10, IL-13, IL-12-p70, IL-16, IL-17, IL-23, IL-27, CXCL-11, CCL-4, CXCL-12, CCL-17, TNF-α or TREM-1 was not detected. Data are given as means ± S.D. (n = 6, each) of normalized intensity. Significance was calculated by 2-way ANOVA. C57Bl6 vs. alb-SREBP-1c mice: *p<0.01.
Figure 6 Cytokine profile secreted from isolated adipocytes of C57Bl6 and transgenic alb-SREBP-1c animals. The cytokine content in supernatant of cultured primary adipocytes was analyzed using the Proteome Profiler™; R&D Systems, (Abingdon, UK). Spot intensities were normalized to background and positive controls set to 100% intensity. Presented numbers on membranes mark targets as follows: (1) CSF-3; (2) CSF-2; (3) CCL-1; (4) sICAM -; (5) IL-1ra; (6) IL-6; (7) CXCL-10; (8) CXCL-1; (9) CSF-1; (10) MCP-1; (11) MCP-5; (12) CXCL-9; (13) CCR-1a; (14) CXCL-2; (15) CCL-5; (16) TIMP-1. Abundance of: CXCL-13, C5a, CCL-11, IFN-γ, IL1-α, IL1-ß, IL-2, IL-3, IL-4, IL-5, IL-7, IL-10, IL-13, IL-12-p70, IL-16, IL-17, IL-23, IL-27, CXCL-11, CCL-4, CXCL-12, CCL-17, TNF-α or TREM-1 was not detected. Data are given as means ± S.D. (n = 6, each) of normalized intensity. Significance was calculated by 2-way ANOVA. C57Bl6 vs. alb-SREBP-1c mice: *p<0.01.CC BY · PubMed Central
Figure 7 Cytokine profile in serum of C57Bl6 and transgenic alb-SREBP-1c animals. The cytokine content in serum was analyzed using the Proteome Profiler™; R&D Systems, (Abingdon, UK). Spot intensities were normalized to background and positive controls set to 100% intensity. Presented numbers on membranes mark targets as follows: (1) C5a; (2) CSF-3; (3) sICAM; (4) INF-γ; (5) IL-12-p70; (6) CXCL-1; (7) CSF-1; (8) MCP-1; (9) TIMP-1; (10) TREM-1. Abundance of: CXCL13, CSF-2, CCL-1, CCL-11, IL1-α, IL1-ß, IL-1ra, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-10, IL-13, IL-16, IL-17, IL-23, IL-27, CXCL-10, CXCL-11, MCP-5, CXCL-9, CCR-1a, CCL-4, CCL-2, CCL5, CXCL-12, CCL-17 or TNF-α was not detected in serum. Data are given as means ± S.D. (n = 6, each) of normalized intensity. Significance was calculated by 2-way ANOVA. C57Bl6 vs. alb-SREBP-1c mice: *p<0.01.
Figure 7 Cytokine profile in serum of C57Bl6 and transgenic alb-SREBP-1c animals. The cytokine content in serum was analyzed using the Proteome Profiler™; R&D Systems, (Abingdon, UK). Spot intensities were normalized to background and positive controls set to 100% intensity. Presented numbers on membranes mark targets as follows: (1) C5a; (2) CSF-3; (3) sICAM; (4) INF-γ; (5) IL-12-p70; (6) CXCL-1; (7) CSF-1; (8) MCP-1; (9) TIMP-1; (10) TREM-1. Abundance of: CXCL13, CSF-2, CCL-1, CCL-11, IL1-α, IL1-ß, IL-1ra, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-10, IL-13, IL-16, IL-17, IL-23, IL-27, CXCL-10, CXCL-11, MCP-5, CXCL-9, CCR-1a, CCL-4, CCL-2, CCL5, CXCL-12, CCL-17 or TNF-α was not detected in serum. Data are given as means ± S.D. (n = 6, each) of normalized intensity. Significance was calculated by 2-way ANOVA. C57Bl6 vs. alb-SREBP-1c mice: *p<0.01.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 68 references

Cited by

Sorted by citations

See all 162

Related

Metadata

Authors
Knebel, B., Haas, J., Hartwig, S., Jacob, S., Köllmer, C., Nitzgen, U., Muller–Wieland, D., & Kotzka, J.
Affiliations
  • Deutsches Diabetes-Zentrum e.V. (DE)
  • Asklepios Klinik St. Georg (DE)
ORCID
Venue
PLoS ONE
Publisher
Public Library of Science (PLoS)
Published
2012-02-21
Volume
7
Issue
2
Pages
e31812
ISSN
1932-6203 (ISSN-L)
DOI
10.1371/journal.pone.0031812
PMC
PMC3283692
OpenAlex
W2015190417
Cited by
162
References
68
Citations by year
2026: 7 · 2025: 8 · 2024: 12 · 2023: 12 · 2022: 12 · 2021: 11 · 2020: 14 · 2019: 11 · 2018: 17 · 2017: 12 · 2016: 11 · 2015: 9 · 2014: 13 · 2013: 9 · 2012: 4
FWCI
8.35
Type
journal article
Language
en
Open access
Licence
Locations
  • PLoS ONE (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Lipid metabolism and biosynthesis
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
Keywords
SREBP-1c, hepatic steatosis, visceral fat, de novo lipogenesis, hepatic lipid accumulation, insulin resistance, transgenic mouse model, fatty acid composition, triglycerides, free fatty acids, lipid metabolism, metabolic disorders
MeSH terms
Fatty Acid Elongases, Acetyltransferases, Animals, Body Composition, Fatty Acids, Fatty Liver, Gene Expression Regulation, Humans, Insulin, Insulin Resistance, Liver, Male, Mice, Transgenic, Organ Specificity, Organ Size, Phenotype, Stearoyl-CoA Desaturase, Transcription, Genetic, Cytokines, Protein Structure, Tertiary, Adipocytes, Intra-Abdominal Fat, Adiposity, Lipogenesis, Mice, Sterol Regulatory Element Binding Protein 1

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review